Sign in

Hannah Wei

Research Analyst at Guggenheim Partners

No verifiable information is available about Hannah Wei serving as an analyst at Guggenheim Partners. Searches across LinkedIn and professional databases yield no evidence of her employment at the firm, coverage of specific companies, track record metrics, or professional credentials such as securities licenses. There is no public career timeline, prior employment history, or recognized financial industry achievement attached to this name in the context requested. As such, no authoritative professional profile can be provided.

Hannah Wei's questions to Ultragenyx Pharmaceutical (RARE) leadership

Hannah Wei's questions to Ultragenyx Pharmaceutical (RARE) leadership • Q2 2025

Question

On behalf of Debjit, Hannah Wei of Guggenheim Partners asked for clarification on which specific bisphosphonate therapies patients in the OI program were on before entering the study.

Answer

Emil Kakkis, Founder, President & CEO, did not disclose the specific types of bisphosphonates used. However, he confirmed that a large fraction of the study participants, greater than 90%, had been on some form of bisphosphonate therapy prior to enrollment, reflecting the study's inclusion of patients with higher fracture rates.

Ask Fintool Equity Research AI